NRx Pharmaceuticals Reports Licensure Of US Patent To Support Use Of NRX-101 For Chronic Pain
Portfolio Pulse from Benzinga Newsdesk
NRx Pharmaceuticals has announced the licensure of a US patent to support the use of NRX-101 for chronic pain. This development could potentially expand the application of NRX-101 beyond its current use.
August 07, 2023 | 10:48 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The licensure of a US patent for NRX-101 by NRx Pharmaceuticals could potentially expand the drug's application, which may positively impact the company's stock.
The licensure of a US patent for NRX-101 could potentially expand the drug's application, which may lead to increased sales and revenues for NRx Pharmaceuticals. This could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100